Search / Trial NCT00000835

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of July 27, 2024

Withdrawn

Keywords

Description

The pseudovirions are virus-like particles generated by in vitro production of HIV-1 viral proteins which are capable of assembly into particles. The presence of gag gene products in addition to envelope glycoprotein should assist in humoral and cellular immunologic responses to internal HIV-1 viral proteins. The pseudovirion vaccine has been tested in preclinical trials in mice, guinea pigs, rabbits, and nonhuman primates with good safety and immunogenicity profile. A total of 78 volunteers will be recruited and randomly assigned to receive pseudovirion vaccine and/or the placebo/adjuvant...

Gender

All

Eligibility criteria

  • Inclusion Criteria
  • Patients must have:
  • Negative ELISA for HIV-1 antibody within 8 weeks of initial immunization.
  • CD4 count >= 400 cells/mm3.
  • Negative Hepatitis B surface antigen.
  • Normal history and physical examination.
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following conditions and symptoms are excluded:
  • Medical or psychiatric condition or occupational responsibilities preclude compliance with the protocol.
  • Present psychosis.
  • Active syphilis (eligible if serology documented to be a false positive or due to remote, i.e., > 6 months treated infection).
  • Active tuberculosis (eligible if positive purified protein derivative test and normal chest x-ray showing no evidence of TB and not requiring isoniazid therapy).
  • Hepatitis B antigenemia.
  • Concurrent Medication:
  • Excluded:
  • Immunosuppressive medications.
  • Patients with the following prior conditions are excluded:
  • History of immunodeficiency, chronic illness, malignancy, or autoimmune disease.
  • History of cancer unless there has been surgical excision followed by sufficient observation period to give a reasonable assurance of cure.
  • History of suicide attempts, recent suicidal ideation or who have past psychosis.
  • History of anaphylaxis or other serious adverse reactions to vaccines.
  • History of serious allergic reaction to any substance, requiring hospitalization or emergent medical care (e.g. Stevens-Johnson syndrome, bronchospasm, or hypotension).
  • Prior Medication:
  • Excluded:
  • Prior receipt of HIV-1 vaccines or placebo recipient in a previous HIV vaccine trial.
  • Use of experimental agents within 30 days prior to study.
  • Live attenuated vaccines within 60 days of study.
  • Medically indicated subunit or killed vaccines (e.g., influenza, pneumococcal) within 2 weeks prior to study.
  • Prior Treatment:
  • Excluded:
  • Receipt of blood products or immunoglobulin in the past 6 months.
  • Risk Behavior:
  • Excluded:
  • Volunteers having identifiable higher risk behavior for HIV infection as determined by screening questions designed to identify risk factors for HIV infection, specifically:
  • History of injection drug use within the last 12 months prior to enrollment.
  • Higher or intermediate risk sexual behavior as defined by the AVEG ( i.e., meeting the criteria for AVEG Risk Group C or D).
  • Volunteers risk behavior for HIV infection will be determined upon information obtained from a questionnaire and from the AIDS Vaccine Evaluation Group (AVEG) risk behavior guidelines.
  • NOTE:
  • Only those volunteers meeting the criteria for AVEG Risk Groups A and B will be enrolled in this study.

Attachments

readout_NCT00000835_2024-07-27.pdf

4.5 MB

NCT00000835_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0